Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05054569
Other study ID # NU 20CC18
Secondary ID IRG-18-163-24STU
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date December 15, 2021

Study information

Verified date December 2021
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop and pre-test an eHealth group intervention for young adult cancer survivors.


Description:

In the first part of this study, the investigators adapted an evidence-based intervention for improving HRQOL to better meet the needs of young adult cancer survivors, and then conducted focus groups with young adult cancer survivors to get feedback on the adapted intervention. In the second part of the study, the investigators will conduct a single-arm pilot trial in which the adapted intervention will be delivered over videoconference via weekly group meetings with a trained facilitator over the course of 10 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date December 15, 2021
Est. primary completion date December 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: - age 18-39 years at the time of participation - diagnosed with a non-metastatic primary cancer between 18-39 years old - completed primary cancer treatment (excepting hormone therapy) 1 month to 5 years prior to enrollment - able to speak and read English - access to internet or cellular connectivity with sufficient bandwidth to participate in videoconferences Exclusion Criteria: - metastatic disease - psychiatric or neurological disorders that could interfere with study participation - considered part of a vulnerable population

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive-Behavioral Stress Management and Health Education
Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.

Locations

Country Name City State
United States Northwestern University Feinberg School of Medicine Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of the adapted intervention Participants will report their satisfaction with individual sessions through brief weekly surveys. Over the course of the 10-week intervention, beginning with the first weekly session through the tenth weekly session
Primary Acceptability of the adapted intervention The number of sessions attended, out of a maximum of 10, will be tracked. Over the course of the 10-week intervention, beginning with the first weekly session through the tenth weekly session
Primary Acceptability of the adapted intervention Immediately after the intervention participants will report their satisfaction with the full program through a brief survey. Immediately after the intervention
Secondary Change in health-related quality of life (HRQOL) from baseline to immediately after the intervention Participants will complete the 27-item Functional Assessment of Cancer Therapy - General. Scores range from 0 to 108, with higher scores reflecting better quality of life. Baseline and immediately after the intervention
Secondary Change in symptom burden from baseline to immediately after the intervention Participants will complete a modified version of the Edmonton Symptom Assessment Scale, which assesses 10 common cancer-related symptoms each on a numerical rating scale ranging from 0 to 10. Higher scores indicate greater symptom burden. Baseline and immediately after the intervention
Secondary Change in cancer-related distress from baseline to immediately after the intervention Participants will complete the 22-item Impact of Event Scale-Revised. Scores range from 0 to 88, with higher scores indicating greater cancer-related distress. Baseline and immediately after the intervention
Secondary Change in stress management skills self-efficacy from baseline to immediately after the intervention Participants will complete subscales from the Measure of Current Status. Subscale scores range from 0 to 8, 0 to 12, or 0 to 20 depending on the subscale. Higher scores indicate more of the construct being assessed. Baseline and immediately after the intervention
Secondary Change in coping from baseline to immediately after the intervention Participants will complete the Brief Coping Orientation to Problems Experienced scale, which yields 14 two-item subscales. Subscale scores range from 2 to 8, with higher scores indicating greater usage of the coping strategy being assessed. Baseline and immediately after the intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases